This Week in Peptide Research: CagriSema's Cardiovascular Trial Baseline, a Retatrutide Safety Case, and Male Osteoporosis Guidance

Peptide Science Daily reviewed new PubMed listings for its tracked compounds from October 5 through October 11, 2026. It was an active week across three distinct storylines: a cardiovascular-outcomes trial published its baseline characteristics, a retrospective real-world database study compared two approved GLP-1-family drugs on heart outcomes, and a case report plus a JAMA news feature both examined the risks of unapproved peptide products sold outside the regulated drug supply. Two more papers updated the treatment evidence for osteoporosis in men and in frail older adults.

In the American Heart Journal, an international team including investigators from the University of North Carolina and Yale described the design and baseline characteristics of REDEFINE 3, a phase 3 cardiovascular-outcomes trial of CagriSema, Novo Nordisk's fixed-dose combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide. Between January 2023 and December 2024, the trial randomized 7,076 adults with established cardiovascular disease and a body mass index of 25 or higher at 575 sites in 24 countries to CagriSema or placebo, both added to standard care. At baseline, mean age was 66; 76 percent had a BMI of 30 or higher; 61 percent had type 2 diabetes, with an average 12-year disease duration and 7.7 percent average HbA1c; and 62 percent had a prior heart attack. The trial aims to confirm CagriSema does not increase the combined risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke, and separately to test whether it reduces that combined risk, plus revascularization, versus placebo. Per its ClinicalTrials.gov registration (NCT05669755), REDEFINE 3 remains active, with a primary completion date in 2027; this week's paper describes only the trial's design and baseline population, not any outcome.

Two more papers examined the broader incretin-drug landscape without new randomized trial data. In the Journal of Diabetes and Metabolic Disorders, researchers used the TriNetX real-world health records network to propensity-match 271,685 adults with type 2 diabetes who started tirzepatide against an equal-sized group who started semaglutide between May 2022 and August 2026. The tirzepatide group had a lower rate of a composite cardiovascular outcome (heart attack, stroke, or heart failure), 4.6 percent versus 5.5 percent, and lower all-cause mortality, 0.6 percent versus 0.9 percent. Because this was a retrospective comparison of existing medical records rather than a randomized trial, propensity matching can reduce but not eliminate the chance that differences between the two patient groups, rather than the drugs themselves, explain the gap. Separately, a narrative review in the journal Peptides from a Beijing Friendship Hospital team examined why both activating and blocking the GIP receptor can produce weight loss in animal studies, and why both effects appear to add to the weight loss produced by GLP-1 receptor agonism. The review cited tirzepatide, an approved dual GIP/GLP-1 receptor agonist, and maridebart cafraglutide, an investigational combination of GLP-1 agonism with GIP receptor blockade still in phase 2 testing, as two different approaches to the same receptor system, and said the underlying brain circuitry involved remains incompletely validated in humans.

Two publications this week focused on the risks of peptide products obtained outside the regulated drug supply. JAMA's Medical News section ran a feature on the growing online market for retatrutide and zenagamtide, two GLP-1-family compounds not approved by any drug regulator, examining why some consumers turn to unapproved sources and the dangers that practice carries. The same week, BMJ Case Reports published a case from University Hospital Zurich describing a woman in her mid-20s hospitalized with five days of persistent nausea, vomiting, and diarrhea after four weekly, dose-escalating subcutaneous injections of an unverified product reported to contain retatrutide. The injections had been administered in a wellness setting by a self-described life coach with no medical qualification, and the patient had not considered them to be medication; an extensive workup, including blood tests, imaging, and a brain MRI, found no other explanation for her symptoms. Her symptoms improved two days after hospital admission and resolved within a week; using the Naranjo causality scale, the authors scored the injected product as a probable cause. Retatrutide is an investigational triple GIP, GLP-1, and glucagon receptor agonist still in Eli Lilly's phase 3 TRIUMPH program, not approved by the FDA, EMA, or TGA, and the case authors emphasized that the product she received was unverified, meaning its actual contents were never confirmed. Both papers point to the same underlying concern: patients may not disclose, or even recognize, wellness-market peptide injections as medication unless clinicians ask directly.

In the Journal of Bone and Mineral Research, the European Calcified Tissue Society's Clinical Action Group published a narrative review and position statement on treating osteoporosis in men, a condition the authors said is under-recognized and under-treated relative to its disease burden. The review reported that bisphosphonates, denosumab, teriparatide, abaloparatide, and romosozumab have all been shown to significantly increase bone mineral density in men, though trial evidence in men remains more limited than in postmenopausal women. For reducing vertebral fracture risk specifically, the review pointed to evidence for zoledronate, alendronate, risedronate, denosumab, and teriparatide; it did not list abaloparatide among drugs with demonstrated fracture-risk reduction in men. The group recommended that men at very high fracture risk start with bone-forming therapy before moving to antiresorptive treatment to maintain the gains. Separately, a systematic review and meta-analysis in Health Science Reports pooled six studies covering 42,851 frail elderly patients, most living in long-term care facilities, who had used anti-fracture medication. Several included studies used teriparatide as a comparison arm against denosumab, zoledronic acid, or sequential therapy with alendronate, but the review's significant pooled finding concerned a different drug class: bisphosphonates were associated with a potential reduction in hip fracture risk and mortality among institutionalized frail elderly patients, with limited non-serious side effects reported. The authors said the real-world impact of these therapies in frail populations still needs further study.

This week's coverage spans one cardiovascular-outcomes trial reporting only its design and baseline population, one retrospective real-world database comparison, one mechanistic review of GIP receptor pharmacology, one JAMA news feature and one case report on unapproved peptide injections, and two papers on osteoporosis drug evidence in men and in frail older adults. Semaglutide, tirzepatide, teriparatide, and abaloparatide are approved drugs; cagrilintide, maridebart cafraglutide, and retatrutide remain investigational, with no FDA, EMA, or TGA approval for any use as of this writing. As with all research covered here, these are findings a given study, review, or case report described, not established clinical fact or treatment guidance.